Skip to main content
SpringerLink
Log in

Bisphosphonates in Bone Metastatic Setting

  • Chapter
  • First Online:
Book cover Bone Metastases

Part of the book series: Cancer Metastasis - Biology and Treatment ((CMBT,volume 21))

  • 1773 Accesses

Abstract

Bisphosphonates (Bps) are a class of drugs approved for treatment of bone metastases. There are two classes, the Nitrogenous-containing and non-Nitrogenous-containing Bps. They act on osteoclasts, inhibiting malignant osteolysis which causes skeletal-related events. These events are defined as pathological fractures, spinal cord compression, bone pain requiring palliative radiotherapy, orthopaedic surgery (such as vertebroplasty, kyphoplasty, and cementoplasty) and malignant hypercalcemia (HCM). In this chapter we will describe the mechanism of action of Bps and the major preclinical and clinical studies which evaluated the efficacy of these agents for the treatment of bone metastases from solid tumors. We will also describe the clinical data on the adjuvant role of Bps in breast and prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Osteoporosis Society (2012) Drug treatment. U.K. National Osteoporosis Society. http://www.nos.org.uk/page.aspx?pid=264&srcid=234. Accessed 7 Aug 2012

  2. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090

    Article  PubMed  CAS  Google Scholar 

  3. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621

    Article  PubMed  CAS  Google Scholar 

  4. Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303–1317

    Article  PubMed  CAS  Google Scholar 

  5. Frith J, Mönkkönen J, Blackburn G et al (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367

    Article  PubMed  CAS  Google Scholar 

  6. Monkkonen H, Lehenkari PP, Kellinsalmi M et al (2004) A new mechanism of action for bisphosphonates: apppi dedicated cytotoxicity of N-BPs. Bone 34:S66–S67

    Google Scholar 

  7. Van Beek E, Cohen L, Leroy I et al (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805–811

    Article  PubMed  Google Scholar 

  8. Van Beek E, Löwik C, van der Pluijm G et al (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722–729

    Article  Google Scholar 

  9. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176

    Article  PubMed  CAS  Google Scholar 

  10. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090

    Article  PubMed  CAS  Google Scholar 

  11. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 96:879–882

    Article  PubMed  CAS  Google Scholar 

  12. Bagi CM (2005) Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57:995–1010

    Article  PubMed  CAS  Google Scholar 

  13. Saad F, Karakiewicz P, Perrotte P (2005) The role of bisphosphonates in hormone- refractory prostate cancer. World J Urol 23:14–18

    Article  PubMed  CAS  Google Scholar 

  14. www.health.gov.il/units/pharmacy/trufot/alonim/533.pdf Zometa prescribing information. Retrieved 8 Oct 2012

  15. www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida. Retrieved 8 Oct 2012

  16. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150–3157

    Article  PubMed  CAS  Google Scholar 

  17. Lopez-Olivo MA, Shah NA, Pratt G et al (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20:2985–2998

    Article  PubMed  Google Scholar 

  18. www.drugs.com/pro/pamidronate.html

  19. www.drugs.com/fda/reclast-zoledronic-acid-safety-communication-new-updated-warning-kidney-impairment-13020.html

  20. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791

    Article  PubMed  CAS  Google Scholar 

  21. Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphospohnates on skeletal morbidity in metastatic cancer. BJM 327:469

    Article  CAS  Google Scholar 

  22. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 20(3):CD003474

    Google Scholar 

  23. Rosen LS, Gordon D, Kaminski M et al (2003) Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced MM or breast cancer: a randomized double blind, multi center, comparative trial. Cancer 98:1735–1744

    Article  PubMed  CAS  Google Scholar 

  24. Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038–2044

    PubMed  CAS  Google Scholar 

  25. Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17:846–854

    PubMed  CAS  Google Scholar 

  26. Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(1):082–090

    Google Scholar 

  27. Wardley A, Davidson N, Barrett-Lee P et al (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. BJC 92:1869–1876

    Article  PubMed  CAS  Google Scholar 

  28. Jagdev SP, Purohit P, Heatley S et al (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433–1438

    Article  PubMed  CAS  Google Scholar 

  29. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  30. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral Ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. BJC 90:1133–1137

    Article  PubMed  CAS  Google Scholar 

  31. Bertoldo F (2012) Uso dei BF nella malattia metastatica. Linee guida Aiom

    Google Scholar 

  32. Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomize, placebo-controlled trial. J Clin Oncol 23:3314–3321

    Article  PubMed  CAS  Google Scholar 

  33. Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 aredia breast cancer study group. J Clin Oncol 16:2038–2044

    PubMed  CAS  Google Scholar 

  34. Body JJ, Diel lJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  35. Kristensen B, Ejlertsen B, Groenvold M et al (1999) Oral clodronate in breast cancer patients with bone metastase: a randomized study. J Int Med 246:67–74

    Article  CAS  Google Scholar 

  36. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701–707

    PubMed  CAS  Google Scholar 

  37. Berruti A ( 2012) Uso dei BF nella malattia metastatica. Linee guida Aiom

    Google Scholar 

  38. Yuen KK, Shelley M, Sze WM et al (2008) Bisphosphonates for advanced prostate cancer. Cochrane Collab 18(4):CD006250

    Google Scholar 

  39. Smith JA Jr (1989) Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 141:85–87

    PubMed  Google Scholar 

  40. Adami S, Mian M (1989) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 116:67–72

    Article  PubMed  CAS  Google Scholar 

  41. Elomma I, Kylmata T, Tammela T et al (1992) Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer. Int J Urol Nephrol 95:1300–1311

    Google Scholar 

  42. Kylmala T, Tammela T, Risteli L et al (1993) Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29A:821–825

    Article  PubMed  CAS  Google Scholar 

  43. Strang P, Nilsson S, Brandstedt S (1997) The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 17:4717–4721

    PubMed  CAS  Google Scholar 

  44. Dearnaley DP, Sydes MR, Mason MD et al (2003) A double-blind, placebo-controlled, randomised trial of oral sodium clodronate for metastatic prostate cancer (MRCPRO5Trial). J Natl Cancer Inst 95:1300–1311

    Article  PubMed  CAS  Google Scholar 

  45. Ernst DS, Tannock IF, Winquist EW et al (2003) Randomized, double-blind, controlled trial of mitoxantron/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335–3342

    Article  PubMed  CAS  Google Scholar 

  46. Small EJ, Matthew RS, Seaman JJ et al (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostatic cancer. J Clin Oncol 21:4277–4284

    Article  PubMed  CAS  Google Scholar 

  47. Saad F, Gleason DM, Murray R (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468

    Article  PubMed  CAS  Google Scholar 

  48. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882

    Article  PubMed  CAS  Google Scholar 

  49. Lee RJ, Saylor PJ, Smith MR (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:88–95

    Article  PubMed  CAS  Google Scholar 

  50. Ernst DS, Tannock IF, Winquist EW et al (2003) Double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335–3342

    Article  PubMed  CAS  Google Scholar 

  51. Dearnaley DP, Mason MD, Parmar MKB et al (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872–876

    Article  PubMed  CAS  Google Scholar 

  52. www.clinicaltrial.gov

  53. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150–3157

    Article  PubMed  CAS  Google Scholar 

  54. Abrahamsson PA, Ostri P, Andersen M et al (2008) Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA®) treatment: NOSAZ—interim analysis. Poster session presented at: 23rd Annual EAU Congress 2008

    Google Scholar 

  55. Kijima T, Fujii Y, Suyama T et al (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624

    Article  PubMed  CAS  Google Scholar 

  56. Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621

    Article  PubMed  CAS  Google Scholar 

  57. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432

    Article  PubMed  CAS  Google Scholar 

  58. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  59. Duck L, Delforge M, Doyan C et al (2009) Zoledronic acid treatment of ≥2 years in patients with metastatic bone disease or multiple myeloma: six-month results from the LOTUZ study. J Clin Oncol 27:9630

    Google Scholar 

  60. Winters JP, Fekrazad MH, Gilliam EH et al (2010) Efficacy and safety of intravenous bisphosphonates beyond two years of use. ASCO Annual Meeting Abstract No: e19619

  61. Zheng M, Rosen L, Gordon D et al (2005) Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases [poster]. Presented at: primary therapy of early breast cancer 9th international conference; 26–29 Jan 2005; St. Gallen; Abstract 104

    Google Scholar 

  62. Aaspro M, Saad F, Costa L (2010) Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 15:1147–1158

    Article  Google Scholar 

  63. Saad F, Hirsh V, Rosen L et al (2006) Continuing benefit of zoledronic acid in patients with bone lesions from multiple myeloma, breast cancer, or prostate cancer who are at high risk for skeletal complications [poster]. Presented at: VI international meeting on cancer induced bone disease 2006; San Antonio; Abstract 130

    Google Scholar 

  64. Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327(7413):469

    Article  PubMed  CAS  Google Scholar 

  65. Aparicio A, Gardner A, Tu Y et al (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220–229

    Article  PubMed  CAS  Google Scholar 

  66. Hiraga T, Williams PJ, Mundy GR et al (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418–4424

    PubMed  CAS  Google Scholar 

  67. Lee MV, Fong EM, Singer FR et al (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602–2608

    PubMed  CAS  Google Scholar 

  68. Mackie PS, Fisher JL, Zhou H et al (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84:951–958

    Article  PubMed  CAS  Google Scholar 

  69. Tassone P, Tagliaferri P, Viscomi C et al (2003) Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88:1971–1978

    Article  PubMed  CAS  Google Scholar 

  70. Senaratne SG, Pirianov G, Mansi JL et al (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468

    Article  PubMed  CAS  Google Scholar 

  71. Jagdev SP, Coleman RE, Shipman CM et al (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126–1134

    Article  PubMed  CAS  Google Scholar 

  72. Matsumoto S, Kimura S, Segawa H et al (2003) Efficacy of combining the third generation bisphosphonate, zoledronate with imatinib mesylate in suppressing small cell lung cancer cell line proliferation. Proc Am Soc Clin Oncol 22:684

    Google Scholar 

  73. Cirak Y, Varol U, Atmaca H et al (2012) Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int 110:E1147–E1154. doi:10.1111/j.1464-410X.2012.11392.x

    Article  PubMed  CAS  Google Scholar 

  74. Schlotter CM, Vogt U, Bosse U et al (2001) Enhancement of breast tumor growth inhibition (BTGI) in vitro through combination of CMF, epirubicin/cyclophosphamide (EC), and epirubicin/paclitaxel (ET) with ibandronate (IB) or zoledronic acid (ZOL). J Bone Miner Res 16(suppl 1):S191

    Google Scholar 

  75. Green J, Gschaidmeier H, Yoneda T et al (2000) Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 11(suppl 4):14

    Google Scholar 

  76. Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278–290

    Article  PubMed  Google Scholar 

  77. Benford HL, McGowan NWA, Helfrich MH et al (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465–473

    Article  PubMed  CAS  Google Scholar 

  78. Almubarak H, Jones A, Chaisuparat R et al (2011) Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10:2

    Article  PubMed  Google Scholar 

  79. Senaratne SG, Mansi JL, Colston KW (2002) The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localization and induces cytochrome c release in breast cancer cells. Br J Cancer 86:1479–1486. Erratum in: Br J Cancer 87:1340

    Google Scholar 

  80. Croucher PI, De Raeve H, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482–492

    Article  PubMed  CAS  Google Scholar 

  81. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    PubMed  CAS  Google Scholar 

  82. Bonjean K, Bellahcene A, Locigno R et al (2001) Zoledronate modulates endothelial cell surface receptors involved in angiogenesis. Proc Am Assoc Cancer Res 42:106

    Google Scholar 

  83. Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897

    PubMed  CAS  Google Scholar 

  84. Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13(15 Pt 1):4482–4486

    Article  PubMed  CAS  Google Scholar 

  85. Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151

    Article  PubMed  CAS  Google Scholar 

  86. Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796:11–18

    PubMed  CAS  Google Scholar 

  87. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612

    Article  PubMed  CAS  Google Scholar 

  88. Allavena P, Sica A, Solinas G (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008(66):1–9

    Article  Google Scholar 

  89. Coscia M, Quaglino E, Iezzi M et al (2010) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14:2803–2815

    Article  PubMed  CAS  Google Scholar 

  90. Mantovani A, Sozzani S, Locati M et al (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol Engl 23:549–555

    Article  CAS  Google Scholar 

  91. Boissier S, Ferreras M, Peyruchaud O et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949–2954

    PubMed  CAS  Google Scholar 

  92. Magnetto S, Boissier S, Delmas PD et al (1999) Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83:263–269

    Article  PubMed  CAS  Google Scholar 

  93. Teronen O, Heikkila P, Konttinen YT et al (1999) MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 878:453–465

    Article  PubMed  CAS  Google Scholar 

  94. Heikkila P, Teronen O, Moilanen M et al (2002) Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13:245–254

    Article  PubMed  CAS  Google Scholar 

  95. Van der Pluijm G, Vloedgraven H, van Beek E et al (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698–705

    Article  PubMed  Google Scholar 

  96. Pickering LM, Mansi JL, Colston KW (2003) Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling. Proc Am Soc Clin Oncol 22:863

    Google Scholar 

  97. Hiraga T, Williams PJ, Ueda A et al (2004) Zoledronic acid inhibits visceral metastases in the 4 T1/luc mouse breast cancer model. Clin Cancer Res 10:4559–4567

    Article  PubMed  CAS  Google Scholar 

  98. Santini D, Pantano F, Vincenzi B (2012) The role of bone microenvironment, vitamin D and calcium. Prev Bone Metastases 192:33–64

    Article  CAS  Google Scholar 

  99. Santini D, Schiavon G, Vincenzi B (2011) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 29(6):e19234

    Article  Google Scholar 

  100. Gnant M, Hadji P (2010) Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res 12(6):216

    Article  PubMed  CAS  Google Scholar 

  101. Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396–1405

    Article  PubMed  CAS  Google Scholar 

  102. Coleman RE, Thorpe HC, Cameron D et al (2010) Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04) [oral presentation]. Presented at 33rd Annual San Antonio Breast Cancer Symposium

    Google Scholar 

  103. Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641

    Article  PubMed  CAS  Google Scholar 

  104. Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 21:2188–2194

    Article  PubMed  CAS  Google Scholar 

  105. Llombart A, Frassoldati A, Paija O et al (2009) Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at American Society of Clinical Oncology 2009 Breast Cancer Symposium

    Google Scholar 

  106. Brufsky A, Harker WG, Beck JT et al (2009) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [poster]. Presented at 32nd Annual San Antonio Breast Cancer Symposium, 2009

    Google Scholar 

  107. Coleman RE, de Boer R, Eidtmann H et al (2012) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2012

    Google Scholar 

  108. Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918–2925

    Article  PubMed  Google Scholar 

  109. Dearnaley DP, Mason MD, Parmar MK et al (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10(9):872–876

    Article  PubMed  CAS  Google Scholar 

  110. Aapro M, Saad F (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol

    Google Scholar 

  111. Paterson AH, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 (1) 59–65

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologia Medica, Università Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy

    Grazia Armento, Marco Imperatori, Vladimir Virzì, Giuseppe Tonini & Daniele Santini M.D., Ph.D.

Authors
  1. Grazia Armento
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Imperatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vladimir Virzì
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniele Santini M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Santini M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Radiation Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

    Vassilios Vassiliou

  2. Dept. Radiation Oncology, University of Toronto Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

    Edward Chow

  3. Dept. Radiation Oncology, University of Patras Medical School, Patras, Greece

    Dimitrios Kardamakis

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Armento, G., Imperatori, M., Virzì, V., Tonini, G., Santini, D. (2014). Bisphosphonates in Bone Metastatic Setting. In: Vassiliou, V., Chow, E., Kardamakis, D. (eds) Bone Metastases. Cancer Metastasis - Biology and Treatment, vol 21. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7569-5_11

Download citation

Publish with us

Policies and ethics

Search

Navigation